Magnesium L-Threonate Dosage Guide: Protocols, Calculator & Safety

Beginner protocols — getting started with magnesium L-threonate:

For general cognitive support / aging brain curiosity: Magnesium L-Threonate (Magtein) 1g orally, once daily in the evening, taken with or without food. Lower starting dose improves GI tolerance and assesses individual response before scaling up. Expected timeline: subtle subjective effects within 1-2 weeks (sleep quality, evening calm); measurable cognitive readouts typically take 4-12 weeks to become apparent. Track sleep quality and subjective mental clarity in a simple journal.

For sleep-focused use (testing whether Magtein adds value over cheaper alternatives): Magtein 1g at bedtime for 2-4 weeks. Honestly compare effects against prior experience with magnesium glycinate or to a 2-week trial of magnesium glycinate 300mg elemental at bedtime. If Magtein is not noticeably better than glycinate for sleep, glycinate is the rational cost-effective choice.

For mild anxiety / evening stress reset: Magtein 1-1.5g split into two doses (0.5-0.75g AM with breakfast, 0.5-0.75g PM with dinner). Combine with L-theanine 200mg AM for daytime calm without sedation.

For older adults with early subjective cognitive complaints: Magtein 1.5g/day split AM/PM initially, with option to escalate to 2g/day after 4 weeks if tolerated and if subjective benefit suggests more is better. This approximates the lower end of the Liu 2016 protocol.

Starting and titration: Most users tolerate 1g/day from the start without issues. For sensitive GI users or those new to magnesium supplements, consider starting at 500mg/day for 1 week, then 1g/day for 1 week, then target dose. Take with food if GI tolerance is a concern.

Timing considerations: (1) Evening dosing is most common and aligned with sleep-support and subjective relaxation effects. (2) AM dosing may be appropriate for cognitive-support framing but can cause drowsiness in some users. (3) Split AM/PM dosing balances cognitive-support claims with sleep-support benefits and is the most evidence-aligned approach (Liu 2016 used divided dosing). (4) With or without food — minimal difference in absorption; with food may improve GI tolerance.

Monitoring: Track: (1) subjective cognitive clarity, memory, focus — but honestly, since these are hard to self-rate, set up simple objective measures like Dual-N-Back scores on a free app once a week, or tracking time to complete a standard crossword; (2) sleep quality (subjective or via wearable); (3) anxiety or stress resilience; (4) any side effects (GI, drowsiness, cognitive dulling, headache). Four-week check-in is appropriate before deciding whether to continue, modify, or discontinue.

Lifestyle foundations: Cognitive-support supplementation works best with: (1) 7-9 hours of sleep nightly; (2) regular aerobic exercise (150+ minutes/week moderate intensity); (3) resistance training 2-3x/week; (4) cognitively engaging activities (learning new skills, reading, puzzles); (5) omega-3 intake (fatty fish or 1-2g EPA/DHA); (6) stress management practices (meditation, time in nature, social connection); (7) adequate hydration; (8) appropriate vitamin D status.

Duration: For general cognitive support, Magtein is typically taken indefinitely if subjective or objective benefits are apparent. For specific targeted trials (testing whether it helps sleep, anxiety, or cognition), a 4-12 week trial is reasonable to assess efficacy, with honest discontinuation if no meaningful benefit emerges.

When to escalate: If 1g/day is well-tolerated and subjective benefits are modest, escalating to the intermediate protocol (1.5-2g/day) after 4-6 weeks is reasonable.

When to discontinue or switch: If no benefits are noted after 8-12 weeks at adequate dose, if GI or cognitive side effects persist, or if cost becomes prohibitive — switching to magnesium glycinate for general magnesium benefits is a rational step down.

Intermediate protocols — therapeutic Magtein dosing:

For age-related cognitive impairment (Liu 2016 protocol): Magnesium L-Threonate (Magtein) 1.5-2g/day, divided AM and PM. Typical split: 1g AM + 1g PM, or 0.75g AM + 1.25g PM (weighted toward evening for sleep overlap). Continue for minimum 12 weeks before assessing efficacy. This is the protocol from Liu 2016 (PMID: 26600199) — the single published RCT with favorable cognitive outcomes. Expected timeline: some subjective improvements within 4 weeks; peak effect on composite cognitive measures at 8-12 weeks. Track with structured cognitive self-assessment (validated tools like the NIH Toolbox Cognition Battery are available online, or simpler measures like trail-making tests).

For stacked nootropic protocol — intermediate user: (1) Magtein 2g/day split AM/PM. (2) Lion's Mane 1g/day with meals. (3) Bacopa 300mg BID (morning and evening, with food). (4) Citicoline 500mg AM. (5) Acetyl-L-Carnitine 500-1000mg AM. (6) Phosphatidylserine 100-200mg/day. (7) Omega-3 EPA/DHA 1.5-2g/day. (8) Vitamin D to sufficiency. Cycle assessment at 8-12 weeks — discontinue any component not demonstrating clear benefit.

For sleep + anxiety combined use: Magtein 2g/day, with dosing weighted toward evening (0.5g AM + 1.5g PM with dinner, or 1g mid-afternoon + 1g at bedtime). Combine with: (1) L-theanine 200-400mg (can be AM or as needed for acute calming); (2) Glycine 3g at bedtime; (3) Ashwagandha 600mg standardized extract/day if chronic stress component present.

For combining Magtein with general magnesium repletion: If the user wants both CNS-targeted threonate dosing AND general elemental magnesium repletion: Magtein 1g AM (96mg elemental) + magnesium glycinate 300mg elemental at bedtime — provides ~396mg total elemental magnesium split across day, with evening glycinate dose also supporting sleep. This is more cost-effective than using 2g Magtein alone to achieve the same elemental magnesium load.

For mild-moderate ADHD adjunct (off-label, experimental): Magtein 1-2g/day split AM/PM may provide adjunct benefit to standard ADHD management; not evidence-established. Must not replace stimulant medications when indicated — discuss with prescribing physician.

For TBI or post-concussion cognitive complaints (experimental): Some practitioners use Magtein 2g/day as part of a neuroprotective stack in post-concussion syndrome. Evidence is preliminary; combine with medical management and rehabilitation. Magtein's NMDA-modulating rationale has theoretical relevance to glutamate excitotoxicity post-TBI but clinical trials are lacking.

Adjusting dosing for body weight: The Liu 2016 protocol does not specify weight adjustment, and 1.5-2g/day is a broad target that works across adult body weights. For subjects at <50kg, consider staying at 1.5g/day. For subjects >100kg, 2g/day (upper end) is appropriate. No evidence that exceeding 2g/day provides additional cognitive benefit.

Monitoring: (1) Baseline: document subjective cognitive state (memory, focus, mental clarity rating 1-10), sleep quality, stress/anxiety level, any cognitive self-assessment measures. (2) 4-week check: reassess same variables. Continue if any improvement; adjust dose or stack if no change. (3) 12-week comprehensive reassessment: decide whether to continue at current dose, escalate to advanced protocol, or discontinue. (4) Ongoing: annual reassessment at minimum for long-term users.

Stacking considerations at intermediate level: Combine Magtein with one or two complementary nootropics initially rather than building large stacks — allows identification of which components are actually contributing. Lion's Mane + Bacopa + Magtein is a reasonable cognitive-focused trio for intermediate users.

Cost-benefit evaluation at intermediate level: At 2g/day Magtein, monthly cost is typically $40-60. Consider whether subjective and objective benefits justify this recurring cost. Honest self-assessment — not marketing-driven assumptions — should guide continuation.

Pregnancy continuation: As with beginners, avoid Magtein in pregnancy in favor of better-studied magnesium glycinate or citrate. If already pregnant on Magtein, switching to glycinate is prudent for the duration of pregnancy.

Advanced protocols and special contexts:

Maximum evidence-based Magtein dose: 2g/day is the upper end of the Liu 2016 protocol and the dose most often used in research and clinical practice. Doses above 2g/day have not been systematically studied for additional cognitive benefit and are more likely to produce GI side effects and drowsiness without clear added efficacy. There is no evidence basis for 3g/day or higher "more is better" approaches, and these should be avoided.

Advanced cognitive decline / early Alzheimer's adjunct (physician-directed only): Some neurologists and integrative medicine practitioners include Magtein 2g/day as part of multimodal interventions for mild cognitive impairment or early Alzheimer's disease — usually alongside standard care (cholinesterase inhibitors, memantine when indicated), Lion's Mane, omega-3, B-vitamin optimization, cardiovascular risk management, and structured cognitive engagement. Not a substitute for standard dementia care. Evidence for Magtein in established Alzheimer's is limited to the Liu 2016 trial (which studied subjective cognitive impairment, not Alzheimer's) and extrapolation from synaptic density rat data. Physician-directed integrative approaches may include Magtein, but patients should not replace evidence-based dementia care with supplements.

Advanced anxiety / trauma-related applications (physician-directed): The Abumaria 2011 fear extinction data in rats has led some integrative psychiatrists to consider Magtein as an adjunct for anxiety disorders, PTSD, or phobia-related conditions — particularly in combination with exposure-based therapies where extinction learning is the therapeutic target. Clinical evidence in these applications is lacking; rationale is inferential. Not a standalone treatment for PTSD or severe anxiety disorders — standard evidence-based care (SSRIs/SNRIs for PTSD, trauma-focused CBT, EMDR) remains first-line.

Magtein in stack with memantine (NMDA antagonist — caution): Memantine is a prescription NMDA antagonist used in Alzheimer's disease and sometimes off-label for other conditions. Combining memantine with high-dose Magtein is theoretically overlapping — both reduce NMDA activity. Clinical experience suggests this combination is often tolerated, but the additive NMDA suppression is real. Discuss with prescribing neurologist or psychiatrist. May require lower memantine dose or lower Magtein dose when combining.

Magtein with ketamine therapy (specialized psychiatric context): Ketamine is used for treatment-resistant depression, typically in supervised clinical settings. The NMDA mechanism of ketamine's antidepressant effect is complex (transient NMDA blockade leading to glutamate surge and downstream BDNF/synaptic effects). Whether Magtein's slower NMDA modulation helps, hinders, or is neutral for ketamine outcomes is unknown. Patients receiving ketamine therapy should discuss any supplements including Magtein with their ketamine provider.

High-altitude cognitive support (experimental): Some users report Magtein helps with cognitive function at high altitude (cerebral hypoxia). No specific research supports this; rationale involves general magnesium cerebrovascular effects. If interested, low-dose trial (1g/day during altitude exposure) is low-risk experimentation.

Perimenopause/menopause cognitive complaints: Perimenopausal and menopausal women frequently report cognitive symptoms ("brain fog," memory changes). Magtein has been used as part of supportive stacks in this context, though specific menopause-cognitive-Magtein research is lacking. Reasonable component of a broader approach including hormone evaluation (and HRT when indicated), sleep optimization, stress management, and other nootropic support.

Athletic cognitive performance: Some athletes use Magtein for reaction time, decision-making, and cognitive endurance in sports requiring sustained cognitive demand. Evidence for acute or chronic Magtein enhancement of athletic cognition is absent. Reasonable low-risk experimentation; not evidence-established.

Long-term users — clinical monitoring: (1) Baseline labs: serum magnesium (though of limited sensitivity for cellular magnesium), kidney function (eGFR, creatinine), vitamin D, B12. Cognitive baseline documentation. (2) Annual reassessment: kidney function, cognitive status, review of continued benefit versus cost. (3) Specific life transitions: starting new medications (particularly bisphosphonates, antibiotics, levothyroxine) warrant timing review; pregnancy warrants switching to glycinate; development of renal impairment warrants dose reduction. (4) Objective cognitive tracking: validated tools (NIH Toolbox, MoCA if clinical), dual-n-back training scores, or structured journaling.

Product quality at advanced use: For chronic long-term use at 2g/day, product quality matters. Prefer: (1) Magtein-branded products from Neurocentria-licensed manufacturers; (2) Third-party tested (NSF, USP, or independent lab verification); (3) Established supplement brands with quality reputations (Life Extension, Pure Encapsulations, Jarrow, Thorne, Double Wood, Designs for Health, and others carrying Magtein); (4) Avoid generic "magnesium threonate" without Magtein certification — the clinical research is specifically on Magtein and generic products of uncertain L-isomer purity have not been studied.

Research directions and emerging applications: Active research areas include Magtein in Alzheimer's disease adjunctive therapy (larger trials in progress), post-concussion syndrome, ADHD, anxiety disorders with exposure therapy, and specific subpopulations (older adults with vascular cognitive impairment, post-chemotherapy cognitive symptoms). These are research-stage and not yet established clinical applications. Independent replication of Liu 2016 at larger sample sizes is the highest priority for establishing robust cognitive efficacy claims; this has been slower than the commercial prominence of the product would predict.

Honest framing at the advanced level: After months-to-years of 2g/day Magtein use, honest users often describe subtle benefits (mildly better sleep, perhaps slightly clearer thinking) that are hard to distinguish from placebo or from concurrent lifestyle factors. The more expansive claims (dramatically improved memory, reversing cognitive aging, becoming demonstrably smarter) are not supported by the evidence and are unlikely to match subjective experience. Set expectations accordingly. If after 6-12 months of consistent use at therapeutic dose with lifestyle optimization you see no meaningful benefit, discontinuation is entirely reasonable — this is not a compound where persistent long-term use in the absence of benefit is indicated.